recurrent clostridioides difficile infection rcdi pipeline insight

DelveInsight’s, “Recurrent Clostridioides difficile Infection (rCDI)  - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Recurrent Clostridioides difficile Infection (rCDI) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Recurrent Clostridioides difficile Infection (rCDI) Understanding

Recurrent Clostridioides difficile Infection (rCDI): Overview

Clostridioides difficile is a gram-positive bacterium that is the cause most implicated in antibiotic-associated diarrhea. The emergence of a newer hypervirulent strain North American pulsed-field gel electrophoresis type 1 (NAP1) has been attributed to the increase in incidence and severity of C. difficile infections (CDI) over the last decade. C. difficile colonizes in the large intestine of humans. Healthy adults with adequate immune response become asymptomatic carriers of the disease. Neonates also have a high rate of asymptomatic carrier rate, owing to a lack of intestinal receptors for C. difficile. The use of antibiotics alters the microbial flora of the large intestine, rendering it susceptible to infection by C. difficile, and the transmission of the disease occurs through the fecal-oral route.

 

"Recurrent Clostridioides difficile Infection (rCDI) - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Recurrent Clostridioides difficile Infection (rCDI) pipeline landscape is provided which includes the disease overview and Recurrent Clostridioides difficile Infection (rCDI) treatment guidelines. The assessment part of the report embraces, in depth Recurrent Clostridioides difficile Infection (rCDI) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence in Recurrent Clostridioides difficile Infection (rCDI) R&D. The therapies under development are focused on novel approaches to treat/improve in Recurrent Clostridioides difficile Infection (rCDI).
• This segment of the Recurrent Clostridioides difficile Infection (rCDI) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Recurrent Clostridioides difficile Infection (rCDI) Recent Developments

• In January 2025, LPOXY Therapeutics announced it signed a term sheet to acquire assets from Xeno Biosciences, including regulatory filings and data from Phase I and Ib trials. LPOXY will use these assets to advance SIDIPREV™, a therapy aimed at preventing Clostridioides difficile infections in hospitalized patients on antibiotics.

Recurrent Clostridioides difficile Infection (rCDI) Emerging Drugs

RBX7455: Rebiotix

RBX2660 is an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection after antibiotic treatment. RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). RBX2660 was developed by Rebiotix, a Ferring company.

Further product details are provided in the report……..

Recurrent Clostridioides difficile Infection (rCDI): Therapeutic Assessment

This segment of the report provides insights about the different Recurrent Clostridioides difficile Infection (rCDI) drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Recurrent Clostridioides difficile Infection (rCDI)

There are approx. 5+ key companies which are developing the therapies for Recurrent Clostridioides difficile Infection (rCDI). The companies which have their Recurrent Clostridioides difficile Infection (rCDI) drug candidates in the most advanced stage, i.e. Phase III include, Rebiotix.

 

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Recurrent Clostridioides difficile Infection (rCDI) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Recurrent Clostridioides difficile Infection (rCDI): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Recurrent Clostridioides difficile Infection (rCDI) therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Recurrent Clostridioides difficile Infection (rCDI) drugs.

Recurrent Clostridioides difficile Infection (rCDI) Report Insights

• Recurrent Clostridioides difficile Infection (rCDI)  Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Recurrent Clostridioides difficile Infection (rCDI) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Recurrent Clostridioides difficile Infection (rCDI) drugs?
• How many Recurrent Clostridioides difficile Infection (rCDI) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Recurrent Clostridioides difficile Infection (rCDI)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Recurrent Clostridioides difficile Infection (rCDI)?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Recurrent Clostridioides difficile Infection (rCDI) and their status?
• What are the key designations that have been granted to the emerging drugs?